When most Americans think of traveling abroad for cancer care, Korea is not the first destination that comes to mind. That is beginning to change — and the data driving that change is hard to argue with. Korea's cancer survival outcomes, published through the National Cancer Center Korea and reported through OECD Health Statistics, place the country among the global leaders in multiple cancer categories. For patients navigating complex cancer diagnoses who are facing long wait times, prohibitive costs, or limited access to specific treatment modalities in the US, Korean oncology represents a serious and credible option.
This article covers what the outcomes data actually shows, why Korean cancer survival rates are as strong as they are, what prostate and breast cancer treatment looks like at Korea's leading hospitals, and what international patients should know before pursuing care in Korea.
The Numbers That Matter
Source: Korea Health Industry Development Institute (KHIDI); OECD Health Statistics; National Cancer Center Korea. 5-year relative survival rates represent the ratio of observed survival to expected survival in the general population. Rates above 100% reflect methodological aspects of relative survival calculation and indicate that survival among cancer patients in that period exceeded general population survival for that age group — often attributable to highly effective screening and early detection programs.
To contextualize these numbers: the US 5-year survival rate for prostate cancer (all stages) is approximately 97.5% according to SEER data — comparable to Korea's 96.9%. US breast cancer 5-year survival (all stages) is approximately 91.2% — below Korea's 94.7%. These comparisons are influenced by screening rates, stage distribution at diagnosis, and population factors, which means they are not direct apples-to-apples comparisons. But the fundamental point stands: Korean cancer outcomes are internationally competitive, not simply "adequate." These are the numbers of a high-performing oncology system.
Why Korean Cancer Survival Rates Are So High
Several structural factors contribute to Korea's cancer outcomes. First and most significantly: early detection through systematic national screening programs. Korea's National Cancer Screening Program provides subsidized screening for six cancers — gastric, colorectal, liver, breast, cervical, and lung — to eligible adults. The result is a population with high rates of early-stage diagnosis, which dramatically improves outcomes across all cancer types. The Fifth National Plan for Cancer Control 2026–2030, announced in February 2026, expands investment in early detection infrastructure, AI-assisted imaging diagnostics, and access to precision oncology treatment options.
Second: hospital volume and specialization. Korea's major cancer hospitals — Asan Medical Center, Samsung Medical Center, and Seoul National University Hospital — handle caseloads that rank among the highest in the world. High surgical and treatment volume correlates with better outcomes in oncology, particularly for complex procedures requiring technical precision.
Third: rapid access to multidisciplinary care. Korean cancer centers operate as integrated systems where surgical oncology, radiation oncology, medical oncology, pathology, and imaging are coordinated through tumor board review — typically within a shorter timeframe than US patients experience navigating fragmented specialty referral networks.
Prostate Cancer in Korea
Korean urology departments at major academic medical centers offer the full spectrum of prostate cancer treatment, including robotic radical prostatectomy (using the Da Vinci surgical system), radiation therapy (external beam radiotherapy and brachytherapy), hormone therapy (androgen deprivation therapy), and active surveillance protocols for appropriate low-risk cases.
Robotic prostatectomy at Korean academic centers is performed by surgeons with case volumes comparable to the most experienced US centers. The procedure has well-established advantages in terms of blood loss reduction, shorter hospital stay, and faster return to continence and erectile function compared to open surgery — outcomes that depend heavily on surgeon experience and volume.
For patients diagnosed in the US who are seeking a second opinion, or who face cost barriers to robotic prostatectomy in the American system, Korean centers offer a credible alternative with outcomes data that justifies serious consideration. Medical records including pathology, imaging, and biopsy reports in English can typically be reviewed remotely before an in-person treatment decision is required.
Breast Cancer in Korea
Korea's breast cancer outcomes reflect both the strength of its early detection infrastructure and the quality of its surgical and oncological treatment. Breast cancer surgeries performed at Korean academic centers include breast-conserving surgery (lumpectomy), mastectomy, sentinel lymph node biopsy, and breast reconstruction using both implant-based and autologous tissue (flap-based) techniques. Oncoplastic breast surgery — which integrates plastic surgical techniques into oncological resection to optimize cosmetic outcomes — is performed by specialized teams at major centers.
Medical oncology protocols at Korean cancer hospitals follow international evidence-based guidelines, including NCCN and ASCO standards, adapted to the specific patient population. Targeted therapies for HER2-positive breast cancer, CDK4/6 inhibitors for hormone receptor-positive disease, and immunotherapy-based protocols are available at Korea's major centers.
For international patients, the breast cancer care pathway at Korean centers typically begins with a comprehensive diagnostic evaluation — imaging, pathology review, and biomarker testing — followed by multidisciplinary tumor board discussion and a treatment plan presented to the patient by the oncology team. English-speaking medical staff and patient coordinators are standard at international patient departments of major hospitals.
"Korea's cancer survival data is not a marketing claim — it is published outcomes from a nationally coordinated oncology system that has invested decades in early detection and surgical excellence. It deserves to be taken seriously."
The Early Detection Advantage
One reason international patients seek Korean hospitals for cancer care is access to Korea's comprehensive health screening programs — particularly the Korean Executive Health Checkup, which combines imaging, laboratory, endoscopy, and oncology biomarker screening in a single multi-day evaluation. This level of integrated screening is available in the US but at significantly higher cost and with greater logistical complexity. Patients who discover cancer at an early, highly treatable stage through Korean screening — either incidentally while seeking other care, or deliberately as the purpose of their visit — benefit directly from Korea's early detection infrastructure.
For a detailed overview of Korean health screening options, see our guide to Korean health screening for international patients.
Top Cancer Hospitals
Samsung Medical Center (Seoul, Gangnam): Home to one of Korea's largest cancer centers, with dedicated comprehensive cancer programs across all major tumor types. The hospital's oncology department operates on a multidisciplinary model with integrated tumor board review. Asan Medical Center (Seoul, Songpa): Affiliated with the University of Ulsan; one of the highest-volume cancer programs in Asia. Particularly recognized for gastrointestinal, urological, and breast oncology. Seoul National University Hospital (Seoul, Jongno): The flagship teaching hospital of Seoul National University College of Medicine; strong across all oncology specialties with particular depth in academic research and clinical trials access.
What International Patients Should Know
Before pursuing cancer care in Korea, international patients should consider: whether the specific diagnosis and treatment complexity is appropriate for international travel (newly diagnosed, stable cancers seeking definitive treatment are typically more suitable than rapidly progressing disease requiring immediate local care); what documentation will be needed for Korean hospital review (pathology reports, imaging on CD or digital transfer, prior treatment records in English); and what follow-up care continuity looks like after return to the US, including communication between Korean treating physicians and US-based oncologists.
Korean cancer hospitals with established international patient programs are accustomed to these coordination needs and will provide comprehensive discharge documentation and post-treatment summaries in English for use by the patient's home providers. KoreMed works with international patients to help navigate Korean cancer care options — contact us to discuss your specific situation.